Previous close | 46.08 |
Open | 46.08 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 46.08 - 46.08 |
52-week range | 26.55 - 51.86 |
Volume | |
Avg. volume | 2,431 |
Market cap | 13.52B |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | 20.95 |
EPS (TTM) | 2.20 |
Earnings date | N/A |
Forward dividend & yield | 1.21 (2.63%) |
Ex-dividend date | 17 May 2023 |
1y target est | N/A |
There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
Today we're going to take a look at the well-established Fresenius Medical Care AG & Co. KGaA ( ETR:FME ). The...
Fresenius Medical Care AG & Co. KGaA ( ETR:FME ) stock is about to trade ex-dividend in three days. The ex-dividend...
Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.
FRANKFURT (Reuters) -Fresenius Medical Care said on Tuesday labour shortages were slowly easing as the German dialysis specialist reported a drop in first-quarter adjusted operating income that was not as steep as some analysts had expected. Adjusted operating income dropped to 354 million euros ($390 million), compared with the median analysts' estimate of 335 million posted on the company's website. It confirmed its full-year outlook, saying adjusted operating income would likely remain flat or decline by up to a "high-single digit" percentage in 2023, which it has described as a transition year towards earnings growth recovery in 2024.
Key Insights Given the large stake in the stock by institutions, Fresenius Medical Care KGaA's stock price might be...
While it may not be enough for some shareholders, we think it is good to see the Fresenius Medical Care AG & Co. KGaA...
Fresenius Medical Care AG & Co. KGaA ( ETR:FME ) came out with its full-year results last week, and we wanted to see...
Fresenius Medical's (FMS) fourth-quarter revenues benefit from strong performance across all segments, especially in the North America and Asia-Pacific regions. However, rising costs hurt margins.
FRANKFURT (Reuters) -German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the diversified healthcare group, it said. The move comes after Elliott Investment Management took a stake in Fresenius last year, sparking speculation the activist investor might push for a break-up of the company. "This is an inflection point for Fresenius," Chief Executive Michael Sen said on Tuesday.
Fresenius Medical Care AG & Co. KGaA / Key word(s): Strategic Company DecisionFresenius Medical Care AG & Co. KGaA initiates firm plans for change of the legal form into a German stock corporation21-Feb-2023 / 19:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Bad Homburg, 21 February 2023. The Supervisory Board of Fre
MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.
Fresenius Medical Care AG & Co. KGaA / Key word(s): MiscellaneousFresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation09-Feb-2023 / 16:26 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Bad Homburg, February 9, 2023Following pre
German healthcare group Fresenius SE said on Thursday it was potentially ready to cede control over Fresenius Medical Care (FMC), after a fall in earnings at the world's largest dialysis company. Shares in FMC were down 3.4% at 1538 GMT, while Fresenius stock surged 4.3% after it said it was considering de-consolidating the subsidiary, meaning its sales would no longer be fully integrated into its financial reports. Elliott Investment Management took a stake in Fresenius SE in October, a person familiar with the matter told Reuters at the time, sparking speculation the activist investor might push for a break up of the diversified healthcare company.
Fresenius Medical Care KGaA (ETR:FME) has had a great run on the share market with its stock up by a significant 25...
How far off is Fresenius Medical Care AG & Co. KGaA ( ETR:FME ) from its intrinsic value? Using the most recent...
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
Today we're going to take a look at the well-established Fresenius Medical Care AG & Co. KGaA ( ETR:FME ). The...
EQS-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): PersonnelFresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care 05.12.2022 / 23:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Helen Giza (54) has been appointed Chief Executive Officer of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, with immediate effect. Previously, she w
Fresenius Medical Care AG & Co. KGaA / Key word(s): PersonnelFresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board05-Dec-2022 / 23:34 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Today, the Superviso
A look at the shareholders of Fresenius Medical Care AG & Co. KGaA ( ETR:FME ) can tell us which group is most...
Fresenius Medical Care (NYSE: FMS), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) have seen their shares slide so far this year. Fresenius, a German company that specializes in healthcare services for kidney dialysis patients, has seen its shares fall more than 54% this year. Fresenius reported third-quarter numbers on Nov. 1, and the results were mixed.
Douglas Dynamics and Fresenius Medical have been highlighted as Zacks Bull and Bear of the Day.